These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 6321306)

  • 1. [Opioid receptor interactions of butorphanol, a narcotic antagonist analgesic, and its metabolites].
    Nozaki M; Niwa M; Hasegawa J; Fujimura H
    Nihon Yakurigaku Zasshi; 1983 Dec; 82(6):443-50. PubMed ID: 6321306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic.
    De Souza EB; Schmidt WK; Kuhar MJ
    J Pharmacol Exp Ther; 1988 Jan; 244(1):391-402. PubMed ID: 2826773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Physical dependence liabilities of butorphanol, a narcotic antagonist, and its main metabolites, norbutorphanol and hydroxybutorphanol].
    Niwa M; Nozaki M; Kamikubo K; Fujimura H; Kadota T; Kai S; Kawano S; Koumura H; Takahashi N
    Nihon Yakurigaku Zasshi; 1983 Dec; 82(6):451-63. PubMed ID: 6686828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regulation of the mu-, delta-, and kappa-opiate receptor subtypes by guanyl nucleotides and metal ions.
    Pfeiffer A; Sadée W; Herz A
    J Neurosci; 1982 Jul; 2(7):912-7. PubMed ID: 6284888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiating aspects of opioid receptor binding by [3H](-) (1R,5R,9R,2''S)-5,9-dimethyl-2-tetrahydrofurfuryl-2'-hydroxy-6,7- benzomorphan hydrochloride ([3H]Mr 2034), a drug preferentially acting on kappa-receptors.
    Ensinger HA
    Arzneimittelforschung; 1985; 35(1A):447-51. PubMed ID: 2985096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of beta-funaltrexamine with [3H]cycloFOXY binding in rat brain: further evidence that beta-FNA alkylates the opioid receptor complex.
    Rothman RB; Bykov V; Mahboubi A; Long JB; Jiang Q; Porreca F; de Costa BR; Jacobson AE; Rice KC; Holaday JW
    Synapse; 1991 Jun; 8(2):86-99. PubMed ID: 1652797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
    Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
    J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative properties of SH-groups at mu, delta and kappa opioid receptor.
    Nozaki M; Niwa M; Fujimura H
    NIDA Res Monogr; 1986; 75():149-52. PubMed ID: 2828961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of butorphanol and its metabolites on the levels of monoamines and their metabolites in the rat brain.
    Niwa M; Nose T; Nozaki M; Tsurumi K; Fujimura H
    Jpn J Pharmacol; 1985 Dec; 39(4):515-28. PubMed ID: 2419614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical characterization of high-affinity 3H-opioid binding. Further evidence for Mu1 sites.
    Nishimura SL; Recht LD; Pasternak GW
    Mol Pharmacol; 1984 Jan; 25(1):29-37. PubMed ID: 6323950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of opioid receptor binding in brain slices.
    Barchfeld-Rothschild CC; Medzihradsky F
    J Neurosci Res; 1987; 18(2):358-65. PubMed ID: 2891857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Further demonstration of kappa opioid binding sites in the brain: evidence for heterogeneity.
    Su TP
    J Pharmacol Exp Ther; 1985 Jan; 232(1):144-8. PubMed ID: 2856939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium regulation of agonist binding at opioid receptors. II. Effects of sodium replacement on opioid binding in guinea pig cortical membranes.
    Werling LL; Brown SR; Puttfarcken P; Cox BM
    Mol Pharmacol; 1986 Aug; 30(2):90-5. PubMed ID: 3016504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A quantitative study of [3H]D-Ala2-D-Leu5-enkephalin binding to rat brain membranes. Evidence that oxymorphone is a noncompetitive inhibitor of the lower affinity delta-binding site.
    Rothman RB; Bowen WD; Herkenham M; Jacobson AE; Rice KC; Pert CB
    Mol Pharmacol; 1985 Mar; 27(3):399-409. PubMed ID: 2579319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of rat brain opioid receptors by cannabinoids.
    Vaysse PJ; Gardner EL; Zukin RS
    J Pharmacol Exp Ther; 1987 May; 241(2):534-9. PubMed ID: 3033219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo binding of benzomorphans to mu, delta and kappa opioid receptors: comparison with urine output in the rat.
    Richards ML; Sadée W
    J Pharmacol Exp Ther; 1985 May; 233(2):425-32. PubMed ID: 2987482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [3H]Ethylketocyclazocine binding to mouse brain membranes: evidence for a kappa opioid receptor type.
    Garzón J; Sánchez-Blázquez P; Lee NM
    J Pharmacol Exp Ther; 1984 Oct; 231(1):33-7. PubMed ID: 6092603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine.
    Chen JC; Smith ER; Cahill M; Cohen R; Fishman JB
    Life Sci; 1993; 52(4):389-96. PubMed ID: 8093631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 5,5'-dithiobis-(2-nitrobenzoic acid) on opiate binding to both the membrane-bound receptor and the partially purified opiate receptor.
    Nozaki M; Cho TM
    J Neurochem; 1985 Aug; 45(2):461-4. PubMed ID: 2989428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The occurrence of different kappa opioid receptors (K1 and K2) in frog (Rana esculenta) brain membranes.
    Benyhe S; Varga E; Borsodi A; Wollemann M
    Acta Physiol Hung; 1990; 76(4):291-4. PubMed ID: 1966577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.